

Information about proposed Board of Directors Annual General Meeting 2022

Proposal for re-election of the current members of the Board of Directors:

Håkan Björklund

Chairman

Born 1956. Ph.D. from Karolinska Institutet, Stockholm. Chairman and Board member since 2016.

Other appointments: Chairman of OneMed and BioPhorum. Board member of Bonesupport. Partner at Tellacq Partners and advisor to Rothschild Private Equity.

Previous appointments: CEO of Nycomed. Extensive international background in the life science industry, from both R&D and sales and marketing. Member of the Board of Directors of several international life science companies including Alere, Coloplast, Danisco and Lundbeck. Member of the Board of Directors for Biovitrum 2001–2007.

Shares: 15,800

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Håkan Björklund is proposed for re-election both as member of the Board of Directors and as chairman of the Board.

Annette Clancy

Born 1954. BSc Hons Pharmacology from the University of Bath, United Kingdom. Board member since 2014.

Other appointments: Non-executive Chair of the Board of Directors of Enyo SA. Member of the Board of Directors of Obseva SA. Investor at Jeito Capital, France.

Previous appointments: Senior Advisor, Biopharmaceutical Team of Frazier Healthcare. Chair of the Board of Directors of Genable Therapeutics and Lysogene SA. Non-Executive Board member of Silence Therapeutics plc. and Clavis Pharma. Head of Transaction and Alliance Management at GlaxoSmithKline.

Shares: 3,414

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Matthew Gantz

Born 1965. BA Princeton University and MBA from Harvard Business School. Board member since 2012.

Other appointments: CEO and member of the Board of Directors of Castle Creek Biosciences Inc. Member of the Board of Directors of the Marine Corps Scholarship Foundation.

Previous appointments: CEO of OxThera AB. Executive Vice President of BTG. Founder and CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc., Vice President Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe, as well as a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division. Former Board member of Life Sciences of Pennsylvania Association.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Helena Saxon

Born 1970. M.Sc. from Stockholm School of Economics. Board member since 2011.

Other appointments: CFO at Investor AB. Member of the Board of Directors of SEB.

Previous appointments: CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.

Shares: 20,000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Staffan Schüberg

Born 1969. BA Hons Business Administration from the London Guildhall University, United Kingdom. Board member since 2020.

Other appointments: CEO and Member of the Board of Directors of the ESTEVE Group. Member of the Board of Directors of Dizlin Pharmaceuticals AB, Hangzhou Jiuyuan Gene Engineering Co. and Corporación Químico Farmacéutico Esteve S.A.

Previous appointments: Mr. Schüberg has extensive experience from the pharmaceutical industry and more than 20 years of experience from Board and executive management roles, including a number of senior positions within Lundbeck A/S, such as Regional Vice President for Southern and Western Europe, President and Chairman of the U.S. operations and Global Chief Commercial Officer on Group level.

Shares: 4,500

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Filippa Stenberg

Born 1985. M.Sc. in economics from Stockholm School of Economics. Board member since 2021.

Other appointments: Investment Manager at Investor AB.

Previous appointments: Analyst at Swedbank LC&I.

Shares: 500

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Proposal for election of a new member of the Board of Directors:**Bo Jesper Hansen**

Born 1958. MD-PhD from the University of Copenhagen.

Other appointments: Member of the Board of Directors of Reapplix A/S, Laborie Inc. and Orphazyme A/S. Senior Advisor at EQT and Global Healthcare Advisor at Goldman Sachs, as well as Venture partner at Wellington Partners, Senior Business Advisor at HBM Ventures and Advisor at Aescap Venture Fund.

Previous appointments: CEO of Swedish Orphan International AB 1998–2010, co-founder of Swedish Orphan Biovitrum AB (publ), and executive chairman of the Board of Directors of Swedish Orphan Biovitrum AB (publ) 2010–2016. Board member of a number of listed companies and extensive experience from several executive positions within research and development in the international pharmaceutical industry.

Shares: 0

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.